Outcomes of antiemetic prophylaxis in children undergoing bone marrow transplantation

Bone Marrow Transplantation

Volumn 30, Issue 2, 2002, Pages 119-124

  Kusnierczyk, N M A ^a   Saunders, E F ^a   Dupuis, L L ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Antiemetics; Bone marrow transplant; Pediatrics

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CHLORPROMAZINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; GRANISETRON; LORAZEPAM; MELPHALAN; METOCLOPRAMIDE; ONDANSETRON; THYMOCYTE ANTIBODY;

ADOLESCENT; ARTICLE; BEHAVIOR DISORDER; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DROWSINESS; DRUG TOLERABILITY; DYSTONIA; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFANT; MALE; NAUSEA AND VOMITING; PATIENT MONITORING; PEDIATRIC HOSPITAL; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECORDING; TREATMENT FAILURE; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; NAUSEA; NEOPLASM; PRESCHOOL CHILD; VOMITING; WHOLE BODY RADIATION;

ADOLESCENT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; NAUSEA; NEOPLASMS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VOMITING; WHOLE-BODY IRRADIATION;

EID: 0036054315     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703579     Document Type: Article

References (24)

1. A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation
2. An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant
3. The antiemetic efficacy of tropisetron plus dexamethasone in patients treated with high-dose chemotherapy and stem cell transplantation
4. Dexamethasone alone or in a combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy
5. Rectus hematoma secondary to vomiting: A complication of conditioning regimen for bone marrow transplantation
6. Evaluation of symptom distress in a bone marrow transplant outpatient environment
7. On the receiving end-patient perception of the side-effects of cancer chemotherapy
8. On the receiving end V: Patient perceptions of the side-effects of cancer chemotherapy in 1993
9. Nausea and vomiting remain a significant clinical problem: Trend over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices
10. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery
11. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the Perugia consensus conference
12. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines
13. Efficacy and safety of ondansetron in pediatric patients undergoing bone marrow transplantation
14. Preliminary evaluation of antiemetics in children undergoing bone marrow transplant conditioning
15. A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation
16. 3 antagonist
17. Controlling conditioning-related emesis in children undergoing transplantation
18. A comparison of the safety and efficacy of ondansetron versus granisetron as prophylaxis against chemo/radiotherapy-induced nausea and vomiting in bone marrow transplantation patients. A double-blinded, randomized, pilot study
19. Ondansetron for efficient emesis control during total body irradiation
20. Assessing the impact of medication therapy on health-related quality of life outcomes in pediatrics
21. Pain in children: Comparison of assessment scales
22. Effectiveness of strategies for preventing acute antineoplastic-induced nausea and vomiting in children with acute lymphoblastic leukemia
23. Delayed nausea and vomiting in children receiving antineoplastics
24. Gastroparesis as a cause of nausea and vomiting after high-dose chemotherapy and haemopoietic stem-cell transplantation